MRNA-2752 is under clinical development by Moderna and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer). According to GlobalData, Phase I drugs for Transitional Cell Cancer (Urothelial Cell Cancer) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MRNA-2752’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MRNA-2752 overview

mRNA-2752 is under development for the treatment of relapsed and refractory solid tumors including non-small cell lung cancer, melanoma, triple negative breast cancer, head and neck squamous cell carcinoma, urothelial cancer and non-Hodgkin's lymphomas including follicular lymphoma and diffuse large B-cell lymphoma. It is administered by intratumor route. The therapeutic candidate comprises three mRNAs that express OX40L, interleukin 23 (IL23) and interleukin 36 gamma (IL36G). It is developed based on messenger RNA expression and N1GL formulation platform. The therapeutic candidate is delivered through lipid nanoparticles.

Moderna overview

Moderna is a biotechnology company that focuses on the development of messenger RNA (mRNA) therapeutics and vaccines. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. Moderna through its mRNA therapeutics platform develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology, and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of MRNA-2752’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.